Evidence map›Paper›PMID 27138982›Full record

ArticleHormones & cancer2016

Relation of Serum Estrogen Metabolites with Terminal Duct Lobular Unit Involution Among Women Undergoing Diagnostic Image-Guided Breast Biopsy.

Hannah Oh, Zeina G Khodr, Mark E Sherman, Maya Palakal, Ruth M Pfeiffer, Laura Linville, Berta M Geller, Pamela M Vacek, Donald L Weaver, Rachael E Chicoine and 12 more

Open access · greenAbstract read
In one paragraph

Article in Hormones & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Associations of Early-Life and Adult Anthropometric Measures with the Expression of Stem Cell Markers CD44, CD24, and ALDH1A1 in Women with Benign Breast Biopsies.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  3. Article
  4. Article
  5. Field cancerization in breast cancer.The Journal of pathology · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Proof of region-specific multipotent progenitors in human breast epithelia.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 2 countries.

Hannah OhDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. hannah.oh@nih.gov.
Zeina G KhodrDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Mark E ShermanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Maya PalakalDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Laura LinvilleDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Berta M GellerThe University of Vermont, Burlington, VT, USA.
Pamela M VacekThe University of Vermont, Burlington, VT, USA.
Donald L WeaverThe University of Vermont, Burlington, VT, USA.
Rachael E ChicoineThe University of Vermont, Burlington, VT, USA.
Roni T FalkDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Hisani N HorneDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Daphne PapathomasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Deesha A PatelDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jackie XiangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Xia XuCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Timothy VeenstraCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Stephen M HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
John A ShepherdUniversity of California at San Francisco, San Francisco, CA, USA.
Louise A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jonine D FigueroaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Gretchen L GierachDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Division of Cancer Epidemiology and GeneticsNational Cancer Institute · USUniversity of Vermont · USLeidos (United States) · US

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
HORMONE-RELATED CANCERSZ01CP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI BRINTON, LOUISE · 1996 to 2008
$11.2M
VERMONT BREAST CANCER SURVEILLANCE SYSTEMU01CA070013 · NCI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI GELLER, BERTA M · 1995 to 2011
$6.7M
Lesion Composition and Quantitative Imaging Analysis on Breast Cancer DiagnosisR01CA166945 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GIGER, MARYELLEN L., SHEPHERD, JOHN ALAN · 2013 to 2017
$3.3M
Intramural NIH HHS Z01 CP010126NCI NIH HHS R01 CA166945NCI NIH HHS U01 CA070013
6 · The paper itself

Abstract

Higher levels of circulating estrogens and estrogen metabolites (EMs) have been associated with higher breast cancer risk. In breast tissues, reduced levels of terminal duct lobular unit (TDLU) involution, as reflected by higher numbers of TDLUs and acini per TDLU, have also been linked to elevated breast cancer risk. However, it is unknown whether reduced TDLU involution mediates the risk associated with circulating EMs. In a cross-sectional analysis of 94 premenopausal and 92 postmenopausal women referred for clinical breast biopsy at an academic facility in Vermont, we examined the associations of 15 EMs, quantified using liquid chromatography-tandem mass spectrometry, with the number of TDLUs and acini count/TDLU using zero-inflated Poisson regression with a robust variance estimator and ordinal logistic regression models, respectively. All analyses were stratified by menopausal status and adjusted for potential confounders. Among premenopausal women, comparing the highest vs. the lowest tertiles, levels of unconjugated estradiol (risk ratio (RR) = 1.74, 95 % confidence interval (CI) = 1.06-2.87, p trend = 0.03), 2-hydroxyestrone (RR = 1.74, 95 % CI = 1.01-3.01, p trend = 0.04), and 4-hydroxyestrone (RR = 1.74, 95 % CI = 0.99-3.06, p trend = 0.04) were associated with significantly higher TDLU count. Among postmenopausal women, higher levels of estradiol (RR = 2.09, 95 % CI = 1.01-4.30, p trend = 0.04) and 16α-hydroxyestrone (RR = 2.27, 95 % CI = 1.29-3.99, p trend = 0.02) were significantly associated with higher TDLU count. Among postmenopausal women, higher levels of EMs, specifically conjugated estrone and 2- and 4-pathway catechols, were also associated with higher acini count/TDLU. Our data suggest that higher levels of serum EMs are generally associated with lower levels of TDLU involution.

Indexed as

AdultBreastBreast NeoplasmsChromatography, LiquidCross-Sectional StudiesEstradiolFemaleHumansHydroxyestronesImage-Guided BiopsyMiddle AgedPostmenopausePremenopauseTandem Mass Spectrometry2-hydroxyestrone4-hydroxyestroneEstradiolHydroxyestrones

Identifiers

PMID27138982
PMCPMC5088060
OpenAlexW2346938215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.